basic information
mesothelioma & asbestos
mesothelioma treatment
mesothelioma research

mesothelioma cancer
malignant mesothelioma
peritoneal mesothelioma
pleural mesothelioma
malignant pleural mesothelioma

picking an attorney
mesothelioma lawyers
settlement examples
asbestos litigation
abuse of lawsuits

news articles
clinical research







Mesothelioma Clinical Trials

Alimta (pemetrexed) plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

This study is currently recruiting patients.

Sponsored by

Eli Lilly and Company
For more information:National Cancer Institute (NCI)

Purpose: This study aims to determine how successful the chemotherapy regimen of Alimta(pemetrexed) plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.

Condition Treatment or Intervention
Pleural Neoplasms
 Drug: Alimta (pemetrexed) and cisplatin

This is a Phase III test

  • In Phase III studies, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely. 

Study Type: Interventional
Study Design: Treatment

Eligilibty: Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both


Inclusion Criteria:

  • the tumor can be surgically removed
  • no prior treatment, either chemotherapy, surgery, or radiation
  • sign informed consent form

Exclusion Criteria:

  • prior use of experimental drug
  • pregnanacy or breast-feeding
  • refusal to have surgery 

Privacy    Terms of Use & Copyright    Home   

Contact Us